Taspoglutide
Overview
Taspoglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist derived from human GLP-1 with amino acid substitutions designed to resist dipeptidyl peptidase-4 degradation and extend duration of action. The peptide activates pancreatic GLP-1 receptors to promote glucose-dependent insulin secretion, inhibit glucagon release, and slow gastric emptying. Its structural modifications were intended to support once-weekly administration for the treatment of type 2 diabetes mellitus.
Key Research Findings
Phase 3 clinical trials (T-emerge program) demonstrated efficacy in glycemic control and weight reduction, with results published in Diabetes Care and related journals between 2010 and 2011. Development was discontinued in 2010 due to concerns over injection site reactions and gastrointestinal tolerability despite meeting primary efficacy endpoints, and the compound never received regulatory approval.
Subcutaneous injection
Investigational
Interested in Taspoglutide?
Find a verified provider experienced with Taspoglutide protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Taspoglutide ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.